Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Replacement in the US Investigational Device Exemption Trial
Why the study?
The Melody valve was developed to extend the useful life of RVOT conduits or bioprosthetic pulmonary valves while preserving RV function and reducing surgical burden in complex congenital heart disease, prompting long-term evaluation.
Does Melody transcatheter pulmonary valve replacement prevent TPV dysfunction and reintervention in patients with RVOT conduit or bioprosthetic pulmonary valve dysfunction?
Comparison
Melody transcatheter pulmonary valve replacement
Design
Investigational Device Exemption trial
Follow-up
Median 8.4 years
Authors
Discussion
Loading...
Member takes
Implication
Warrants extended surveillance for dysfunction after Melody TPV; extends observational durability data but leaves comparative effectiveness open.
Structured PICO
Does Melody transcatheter pulmonary valve replacement prevent TPV dysfunction and reintervention in patients with RVOT conduit or bioprosthetic pulmonary valve dysfunction?
P
Population
171 subjects with right ventricular outflow tract (RVOT) conduit or bioprosthetic pulmonary valve dysfunction (150 underwent implantation), median age 19 years.
I
Intervention
Melody transcatheter pulmonary valve (TPV) replacement
O
Outcome
Freedom from transcatheter pulmonary valve (TPV) dysfunction (composite of freedom from reoperation, reintervention, moderate or severe pulmonary regurgitation, and/or mean RVOT gradient >40 mm Hg)composite
Ten-year outcomes of the Melody TPV show sustained benefits with 90% freedom from mortality and 79% freedom from reoperation, though TPV dysfunction occurred in nearly half of patients by 10 years.
Cite This Study
Jones et al. (2021) studied this question.